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Objectives: In light of recent results from observational studies showing prolonged
survival in subjects taking long-acting b2-agonists (LABA) and/or inhaled corticos-
teroids (ICS) for chronic obstructive pulmonary disease (COPD), we investigated their
cost-effectiveness (CE).
Methods: Costs and survival data were collected for a sample of members enrolled
in a large Health Maintenance Organization in the United States. An observational
study design was used to evaluate cumulative costs and health benefits of LABA, ICS,
ICS+LABA, or comparison drugs. Survival was estimated using a parametric regression
model. Costs were adjusted for censoring and prognostic factors. CE was evaluated
over a time horizon of 36 months and the remaining lifetime of subjects.
Results: Over 36 months, life expectancy and costs were: 2.4 years (95% confidence
interval (CI): 2.3; 2.5) and $28,030 (CI: $23,400; $33,570) for not receiving ICS orElsevier Ltd. All rights reserved.
ness acceptability curve; CI, 95% confidence interval; COPD, Chronic obstructive pulmonary
EV1, Forced expiratory volume 1 s; HMO, Health Maintenance Organization; HR, Hazard ratio;
atio; ICS, Inhaled corticosteroids; LABA, Long-acting b2-agonists; SD, Standard deviation
partially supported by GlaxoSmithKline Pharmaceuticals.
06 8691; fax: +1 604 331 8446. Oxford Outcomes Ltd., 450-688 West Hastings Street, Vancouver,
outcomes.net (A.R. Levy).
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Economic evaluation of treatments for COPD 1535LABA; 2.6 years (CI: 2.6; 2.7) and $35,170 (CI: $29,970; $40,620) for ICS alone; 2.6
years (CI: 2.5; 2.7) and $27,380 (CI: $21,780; $32,510) for LABA alone; and, 2.7 years
(CI: 2.6; 2.8) and $33,780 (CI: $28,700; $39,440) for subjects treated with ICS+LABA.
The lifetime analysis showed similar trends.
Conclusions: There is an acute need to find effective, life-extending treatments for
persons with COPD. ICS, LABA or their combination represent promising treatment
options and are currently being tested in randomized trials. If the impact on survival
seen in these trials compares to that seen in observational studies, LABA and the
combination treatment are likely to be cost-effective in the United States.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a
leading cause of morbidity and mortality worldwide
and results in a substantial economic and social
burden to all countries. The global burden of COPD
has been increasing and is expected to continue to
escalate in the coming decades. COPD was the
eleventh leading cause of disability and the fifth
leading cause of death in 2000.1 It is projected that
by 2020, COPD will become the fifth leading cause
of disability and third leading cause of death.2
Managing the chronic symptoms and exacerbations
is also associated with elevated utilization of
health care services and costs,3–6 including work
absenteeism and lost productivity.7–11
Other than smoking cessation,12 to date, only
oxygen therapy has been shown to prolong survi-
val.13–15 Other medical treatments have been
aimed primarily at relieving symptoms and mana-
ging exacerbations.14,16–23 Nevertheless, there
have been improvements in the survival of persons
with COPD over the last several decades, suggesting
that survival benefits of treatment may exist.24–26
Given the enormous burden attributable to the
disease, any new medical treatments that prolong
survival would have a wide indication among
patients with COPD.
New treatments that are currently being tested
in randomized trials of subjects with COPD are
long-acting b2-agonists (LABA) such as salmeterol
and inhaled corticosteroids (ICS) such as fluticasone
propionate. Recent randomized studies showed
that lung capacity increased significantly among
subjects receiving salmeterol alone and even
greater benefit was experienced when fluticasone
was added.27,28 It remains to be proven whether
the improvements observed in bronchodilation
derived from LABA and ICS also lead to prolonged
survival. However, evidence from a recent study of
survival among persons with COPD from two health
maintenance organizations (HMO) in the United
States suggests that there may be a survival
advantage.22,29 Relative to subjects not receivingother medication, that study showed statistically
significant reduced risks of death: for the ICS group,
the hazard ratio (HR) was 0.6 (95% confidence
interval (CI): 0.5; 0.8), for the LABA group
HR ¼ 0.55 (CI: 0.3; 0.9), and for ICS and LABA in
combination HR ¼ 0.3 (CI: 0.2; 0.7).
Using survival and cost data from one of those
HMOs, we investigated the expected costs of care,
the gains in life expectancy and the potential cost-
effectiveness (CE) of ICS and LABA alone or in
combination for treating subjects with COPD.Methods
Using survival analysis techniques, we conducted a
CE analysis of competing strategies for treating
COPD over both the 36 months of the original study
(i.e.
’ ’
within-study’’ analysis) and the remaining
lifetime of subjects (i.e.
’ ’
lifetime’’ analysis that
was extrapolated over the lifetime of the cohort).
The perspective was that of a third party payer,
such as a managed care organization or HMO. In
addition to ICS, LABA and the combination ICS+LA-
BA, we estimated costs and effects for a group of
other medications including short-acting b-ago-
nists, xanthine, anticholinergic or combined
bronchodilators.Data sources and survival study design
Subject level data on survival, costs and prognostic
factors were derived from administrative records
from the Lovelace Patient Database. The database
contains records of hospital episodes, physician
visits and dispensed medications for a 200,000-
member HMO in New Mexico, the Lovelace Health
Plan. Survival was determined using records of
death certificates obtained from New Mexico vital
records bureau for the years 1995–2000. These
were linked deterministically to patient records
based on name and social security number. Esti-
mates of survival were obtained from a published
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ness.29 In that study, subjects were assigned to
either an
’ ’
exposed’’ group defined as having at
least 90 days exposure to ICS, LABA or both, or to a
’ ’
comparison’’ group defined as having no exposure
to ICS or LABA, but at least 90 days exposure
to other COPD drugs. Other inclusion criteria
included: (1) enrollment in the HMO between
1 January 1995 and 31 December 2000 (the study
period); (2) at least two outpatient encounters
or at least one hospital admission coded as chronic
bronchitis, emphysema, or COPD during the
study period; (3) no evidence of cystic fibrosis,
bronchiectasis, or lung cancer; (4) age 40 years or
older; and, (5) at least 12 months of HMO
enrollment prior to their study enrolment. The
follow-up period began on the first day following
the 90th day of drug exposure and continued until
death, disenrolment or 31 December 2000, which-
ever came first. For each initial exposure group,
subjects were assumed to be regular users of the
medications.
To compare the likelihood of survival between
treatment groups over 36 months, the investigators
used a Cox proportional hazards model that
included prognostic factors including demographic
variables, comorbid medical conditions (Charlson
score) and severity of COPD.
Costs were estimated as follows. Subject-level
health care charges from the Lovelace Patient
Database captured the following categories of
health care utilization: outpatient prescription
medications, ambulatory care and hospitalizations.
Ambulatory care included all encounters such as
physician visits, radiology, laboratory testing, re-
habilitation, and other outpatient procedures and
services.Economic study design and analytical
techniques
To derive incremental CE ratios, we estimated the
life expectancies (life-years) for each treatment
group. Although the semi-parametric Cox propor-
tional hazards model can be used to calculate
hazard ratios to determine relative measures of
treatment effect, it does not yield a direct
specification of the baseline hazard function.30,31
Determining the baseline hazard function is neces-
sary to be able to estimate life expectancy. To do
so, we used a parametric proportional hazards
regression model based on a Gompertz distribution.
The Gompertz model is specified to increase
exponentially with time and is, therefore, more
likely to reflect the survival patterns and poor long-term prognostic of individuals with COPD.32 Over
the 36 months in the
’ ’
within-study’’ analysis,
parameter estimates and hazard ratios between
non-parametric and parametric techniques re-
mained similar. The covariates included in the
regression model were the same as those used for
adjustment in the survival study.29 To evaluate
mean survival, we calculated the area under each
fitted treatment-specific survival curve33 by pre-
viously setting covariates at their mean values.
Mean survival was estimated both for the within-
study analysis over 36 months and using the
extrapolated survival curves over the remaining
lifetime of subjects.
Because some subjects were censored, data on
costs were incomplete. We accounted for the bias
introduced by ignoring costs among censored
subjects by partitioning the original time interval
of the cost dataset into smaller subintervals and
then applying weights to reflect the censoring
patterns over time. This also results in improved
statistical efficiency.34–36 Prior to applying weights
to the cost data to address censoring, regression
techniques can be used to adjust costs for potential
confounders, which may include known prognostic
factors.
We therefore created a costing dataset with
monthly time increments. The costs were assigned
to the month in which they were accrued. When
health resources used for treating a particular
event were spread over more than a month, the
costs were apportioned to each month according to
the respective number of days of utilization. To
adjust for prognostic factors, we estimated a
random-effects model using generalized least
squares estimator that included the same covari-
ates as in the analysis of survival. (Details of the
random effects model parameters and coefficients
are available from the authors upon request.) We
then used the estimation results to generate fitted
values of monthly costs. For the censoring adjust-
ments in the within-study analysis, we relied on the
inverse probability weighted method.34,36 The
covariate-adjusted monthly costs were multiplied
by the inverse of their monthly probability of being
observed (or uncensored). For each treatment, the
monthly probabilities of remaining uncensored
were estimated by the Kaplan–Meier survivor
function for time-to-censoring. Once costs had
been weighted, we summed and averaged over
the total number of subjects to derive the average
cumulative cost per treatment option. A similar
approach to weight costs using the probability of
survival at each time point was used for the
lifetime analysis.46 Costs were cumulated over the
remaining lifetime of subjects which had been
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analysis.
As the cost figures represented charges rather
than the actual cost of resource consumption, we
transformed all estimates using the 2001 Lovelace
Health Systems cost-to-charge ratio of 0.732
published by the Centers for Medicare and Medicaid
Services.37 Cost and outcomes were discounted at a
rate of 5% per annum and all costs are reported in
2001 US dollars. For transparency, we also repli-
cated the analysis without discounting costs and
outcomes.38
To assess the incremental CE of treatments we:
(1) rank-ordered different therapies according to
their respective life expectancy, (2) used usual
criteria for making comparisons between multiple
alternatives in CE analyses,39 and (3) calculated the
incremental CE ratio (ICER) between pairs of
treatment options by taking the difference in
expected costs and dividing it by the difference in
life expectancies.Uncertainty analysis of cumulative costs and
life expectancy
To evaluate the uncertainty and build 95% con-
fidence intervals around the estimates of cumula-
tive costs and life expectancy, we used a non-
parametric bootstrapping technique based on 1000
resamples.40–43 Because this technique does notTable 1 Characteristics of 1154 subjects overall and by st
with COPD between 1995 and 2000.
Overall
(N ¼ 1154)
Compariso
or LABA (N
Age (7SD) 65.9 (10.1) 66.4 (9.6)
Gender—% male 51 55
Proportion with Charlson score
X1 (based on hospitalization)
0.1 0.09
Proportion with Charlson score
X1 (based on outpatient
encounters)
0.3 0.35
Percent with X20 COPD
outpatient visits in year prior
to study enrolment
17.9 16.1
Percent with ED encounter in
year prior to study enrolment
3.8 3.7
Percent with hospital
admission in year prior to study
enrolment
5.1 6.6
Number of deaths (%) 208 (18) 78 (28.5)
Abbreviations: HMO: Health Maintenance Organization; COP
corticosteroids; LABA: Long-acting b2-agonists; SD: Standard deviarely on the specification of a particular distribution
for costs and life expectancy, it is considered
appropriate when the distribution of the data is
skewed and traditional hypothesis tests would not
be reliable. It also preserves the covariance
structure of the data between costs and effects.
The 1000 bootstrap resamples of costs and life
expectancies for the within-study and lifetime
analyses were plotted on CE planes. These are
useful devices to provide a graphical representa-
tion of uncertainty surrounding the point estimates
for each treatment group. On the CE plane, the
costs are shown on the ordinate (y-axis) and the
effects on the abscissa (x-axis). The difference in
costs and effects between the two treatments
shows the joint distribution of these two para-
meters.
An alternative presentation is called a cost-
effectiveness acceptability curve (CEAC). This
curve shows the probability that a medication is
cost-effective compared with the alternative for a
range of maximum acceptable values for ICERs.
They present an alternative to having confidence
intervals for the incremental cost-effectiveness
ratios.40,41 The CEAC is derived by repeatedly
sampling from the joint distribution of incremental
costs and incremental effects using a resampling
technique called
’ ’
bootstrapping’’. These curves
are created to yield the probability that a treat-
ment is cost-effective over a range of dollar values
that a decision-maker would be willing-to-pay forudy group enrolled in the Lovelace HMO and diagnosed
n (no ICS
¼ 274)
ICS
(N ¼ 538)
LABA
(N ¼ 130)
ICS+LABA
(N ¼ 212)
64.9 (10.1) 66.1 (10.5) 62.8 (9.8)
52 50 45
0.1 0.09 0.06
0.3 0.28 0.25
15.8 16.2 26.9
4.1 1.5 4.7
4.8 3.1 5.2
95 (17.7) 17 (13.1) 18 (8.5)
D: Chronic obstructive pulmonary disease; ICS: Inhaled
tion; ED: Emergency department.
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Y.M. Gagnon et al.1538individuals to gain one extra year of life. We
generated CEAC for each treatment option to
determine the most favorable alternatives over
the range of willingness-to-pay (WTP) values.
All statistical analyses were conducted using SAS
8.0s for Windowss, STATA 7.0s for Windowss and
the CEACs were generated using Excels for
Windowss.Li
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Figure 1 Adjusted survival curves for each treatment
group estimated from the Parametric Survival Model for
1154 subjects enrolled in the Lovelace HMO and
diagnosed with COPD between 1995 and 2000: (a)
within-study analysis and (b) lifetime analysis. Note:
The vertical line at month 36 represents the start point of
extrapolated survival estimates; adjusted survival curves
were estimated with covariates set at their mean values.
Abbreviations: COPD: Chronic obstructive pulmonary
disease; ICS: Inhaled corticosteroids; LABA: Long-acting
b2-agonists.Results
The cohort included 1154 subjects with a mean age
of 66 years and approximately equal proportions of
women and men (Table 1). The largest share of
costs originated from hospitalizations (Table 2)
which accounted for 50% of the total average
monthly cost, followed by ambulatory care at 38%
and costs of outpatient medications at 12%. Over 36
months, the three components as a share of total
costs remain relatively stable (data not shown).
Some differences between groups in some of the
demographic variables and measures of disease
severity were found (Table 1).
The adjusted survival curves estimated from the
parametric Gompertz model are presented in Fig.
1. Those curves show the survival patterns observed
for each treatment group in the within-study and
lifetime analyses.
After rank-ordering the four treatment options
by their estimates of life expectancies, the ICS
alone and the
’ ’
comparison’’ group of no ICS or
LABA in the within-study analysis both show higher
costs and lower effectiveness when compared to
the next option of LABA alone (Table 3). Those
options were considered
’ ’
dominated’’ (i.e. lower
effectiveness at greater cost) so we only estimated
the ICER between the remaining two alternatives of
LABA and the ICS+LABA combination. In the lifetime
analysis, only ICS was dominated so that the ICER
was also calculated for LABA and the
’ ’
comparison’’
group of no ICS or LABA.
Table 3 also shows the cumulative costs and life
expectancies for the within-study and lifetimeTable 2 Description of monthly costs (2001 $US) of trea
diagnosed with COPD between 1995 and 2000.
Variable Mean (proportion of total cost)
Outpatient medication 146 (0.12)
Hospitalization 639 (0.50)
Ambulatory care 487 (0.38)
Total cost 1,272
Abbreviations: HMO: Health Maintenance Organization; COPD: Chanalyses including the 95% confidence intervals
derived from the analysis of uncertainty. The 1000
bootstrap replicates of cost and effect pairs are
shown on the CE plane for the within-study analysisting 1154 subjects enrolled in the Lovelace HMO and
SD Minimum Maximum Skew Kurtosis
152 0 3955 3 34
4605 0 168,179 15 308
1542 0 85441 29 1348
5061 0 168,179 13 239
ronic obstructive pulmonary disease; SD: Standard deviation.
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Table 3 Cumulative costs, life expectancy and incremental cost-effectiveness ratios for 1154 subjects enrolled
in the Lovelace HMO and diagnosed with COPD between 1995 and 2000—within-study and lifetime analyses.
Costs (US $) Discounted
costs (US$)
Life expectancy Discounted life
expectancy
Incremental
cost (US$) per
year of life
gainedy
Within-study analysis (36 months)
Comparison (no
ICS or LABA)
29,250 (24,420,
35,050)
28,030 (23,400,
33,570)
2.52 (2.40,
2.67)
2.41 (2.30,
2.55)
Dominatedz
ICS 36,840 (31,410,
42,500)
35,170 (29,970,
40,620)
2.72 (2.67,
2.80)
2.60 (2.56,
2.68)
Dominatedz
LABA 28,690
(22,8730,
34,060)
27,380 (21,780,
32,510)
2.75 (2.64,
2.87)
2.63 (2.53,
2.74)
—
ICS+LABA 35,440 (30,090;
41,440)
33,780 (28,700;
39,440)
2.83 (2.76,
2.91)
2.70 (2.64,
2.78)
91,430
Lifetime analysis
Comparison (no
ICS or LABA)
55,170 (35,480,
85,060)
48,950 (31,800,
72,500)
4.34 (3.53,
5.94)
3.88 (3.25,
5.02)
—
ICS 84,290 (57,970,
129,500)
71,860 (50,900,
103,180)
5.88 (4.88,
8.33)
5.06 (4.34, 6.6) Dominatedz
LABA 68,230 (36,890,
116,310)
57,500 (32,380,
91,720)
6.17 (4.68,
9.38)
5.27 (4.19,
7.21)
6110
ICS+LABA 97,190 (58,320,
165,370)
79,560 (50,020,
122,070)
7.39 (5.59,
11.59)
6.14 (4.89,
8.63)
27,570
Abbreviations: HMO: Health Maintenance Organization; ICS: Inhaled corticosteroids; LABA: Long-acting b2-agonists; COPD:
Chronic obstructive pulmonary disease.
Costs and outcomes discounted at 5% per annum after the first year; monetary values have been rounded to the nearest ten.
yIncremental cost-effectiveness ratio based on discounted values. Calculated relative to the next less costly non-dominated
treatment strategy, eg in the within study analysis, for ICS alone relative to ICS+LABA calculated as: (33,78027,380)/
(2.702.63) ¼ 91,430.
z
’ ’
Dominated’’ means that the treatment is both more costly and less effective than the LABA alternative.
Economic evaluation of treatments for COPD 1539(Fig. 2) and the lifetime analysis (Fig. 3). There was
higher uncertainty surrounding the results of the
lifetime analysis than the within-study analysis.
This is represented by the wider confidence
intervals around costs and effects (Table 3) and
the broader dispersion of the bootstrap replicates
(Fig. 3). Although the point estimates for the
incremental CE ratios would indicate that LABA
dominates both ICS and no ICS in the 36-month
analysis and that ICS is still dominated in the
lifetime analysis, the substantial uncertainty
surrounding the estimates of costs and effects
prevents us from making this conclusion. In those
circumstances, the more useful approach to
analyze uncertainty is through CEACs for each
treatment.
The CEAC for results of the within-study and
lifetime analyses are shown in Figs. 4 and 5,
respectively, using WTP values ranging from $0 to
$200,000 per year-of-life gained. The CEAC for the
within-study analysis indicated that for lowervalues of WTP (i.e. less than $91,000 per year of
life gained), the treatment with LABA was the most
favorable option. For values higher than $91,000
the combination ICS+LABA then became the one
with the highest probability of being cost-effective.
For the lifetime analysis, the comparison group
of no ICS or LABA was the most favorable option for
very low values of WTP (i.e. less than $6,100).
Then, for values between $6,100 and $27,500,
LABA had the highest likelihood of being cost-
effective. Above a WTP of $27,500 the combination
ICS+LABA provided the best value for money.Discussion
We found that treatment with LABA alone and in
combination with ICS provided gains in life for
persons with COPD that may be considered cost-
effective at conventional levels. These findings
ARTICLE IN PRESS
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Figure 2 Results of 1000 bootstrapped costs and effects for each COPD treatment—within-study analysis.
Abbreviations: COPD: Chronic obstructive pulmonary disease; ICS: Inhaled corticosteroids; LABA: Long-acting b2-
agonists; Note: Larger white circles represent the point estimates for each treatment group and the thick black line is
the cost-effectiveness efficiency frontier joining non-dominated treatment alternatives.
Y.M. Gagnon et al.1540warrant consideration given the lack of effective
treatments for this condition. Two published
analyses have previously examined the CE of
salmeterol and fluticasone propionate.44,45 How-
ever, no study has described the CE of the four
treatment options including ICS, LABA, ICS+LABA
and other medications but no intake of ICS or LABA.
Additionally, our study is the only one that
investigated the CE of these treatments using a
health outcome of survival and that calculated life
expectancy.
Because there is clear evidence that ICS and
LABA relieve the symptoms of COPD and improve
quality-of-life,19,21,27,46–49 many investigators ex-
amine markers of lung capacity or the rate of
exacerbations of COPD. Evidence of an increased
benefit on lung function from combination therapy
is starting to accumulate. In a 12-month rando-
mized clinical trial, the combination of salmeterol
and fluticasone resulted in significantly improved
lung function (FEV1) against placebo, salmeterol
alone or fluticasone alone.28 That study was not
powered to detect differences between treatments
for other outcomes such as the total rate of
exacerbations or survival.A significant reduction in the rates of COPD
exacerbations for ICS versus placebo was demon-
strated in several randomized controlled trials
presented in a systematic review.50 Although the
investigators of the systematic review did not find a
statistically significant effect of ICS on all-cause
mortality, there was a trend suggestive of a survival
benefit.
Considering the results from other observational
studies suggesting survival benefits,24,25 rando-
mized studies are being designed to investigate
whether survival benefits are reproduced in an
experimental setting. In the absence of randomized
data, we relied on an observational dataset from a
large HMO in the United States. The dataset had
the advantage of being more representative of
actual treatment patterns and, thus, carries a
greater potential for generalizability of the results.
However, the potential for greater generalizability
must be weighed against a greater likelihood of
confounding by known and unknown risk factors
because subjects were not randomized to their
treatment regimens. Of particular concern in a
non-randomized study is confounding by indication,
i.e. subjects are given a treatment specifically
ARTICLE IN PRESS
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Figure 3 Results of 1000 bootstrapped costs and effects for each COPD treatment—lifetime analysis. Note: Larger
white circles represent the point estimates for each treatment group and the thick black lines represent the cost-
effectiveness efficiency frontier joining non-dominated treatment alternatives; Abbreviations: COPD: Chronic
obstructive pulmonary disease; ICS: Inhaled corticosteroids; LABA: Long-acting b2-agonists.
Economic evaluation of treatments for COPD 1541because the physician believes that it would have
the greatest beneficial effect.51,52 Also, the mea-
sures of disease severity in this study were based on
proxy information (i.e. health care utilization).
While analytical techniques are available to control
for potential confounders, it is not possible to be
entirely confident that all relevant factors have
been included. Future studies would benefit from
inclusion of information on severity of illness from
spirometric measurements. By selecting the same
covariates used as predictors of survival to adjust
costs, the potential for some residual confounding
may introduce some bias in the estimates of costs.
The need for including covariate adjustments to
guard against confounding that would result in
biased estimates of CE are also highlighted by the
presence of imbalances in the distribution of
subject characteristics between treatment options.
Additionally, in order to emulate a randomized
trial, the original survival study started the follow-
up after the ninetieth day of exposure to LABA, ICS,
ICS+LABA, or comparison drugs. This meant that
subjects receiving between 1 and 90 days of thesetreatments were excluded and that the date of
entry into the cohort was different for different
groups of subjects. This can create what has been
called an
’ ’
immortal time bias’’53 in which, by using
this definition of exposure, the outcome cannot
occur during some period in which exposure
occurred. This can potentially result in an over-
estimation of risk or benefit if subjects do not
survive long enough to be prescribed the exposure
of interest, and are categorized as unexposed. By
artificially inflating the outcome rate among
unexposed subjects, a treatment can appear more
beneficial than it actually is. One solution is to
design a study in which exposures are allowed to
vary over time.53 However, study designs that
incorporate time-dependent use medications are
subject to protopathic bias, which can arise in
situations where medications are used to treat
acute symptoms of COPD.54 Some investigators
argue that a time-dependent analysis should not
be used to evaluate the effects of chronic
pharmacologic therapies when they may also be
used to treat acute exacerbations.55 These issues,
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Figure 4 Cost effectiveness acceptability curves showing strategies most likely to be cost-effective for 1154 subjects
enrolled in the Lovelace HMO and diagnosed with COPD between 1995 and 2000—within-study analysis. Note: The
willingness-to-pay is the maximum amount that a decision-maker would pay for a gain of one year in life expectancy.
LABA is the most cost-effective option until willingness-to-pay reaches $91,429 per year of life gained and ICS+LABA
thereafter. Abbreviations: HMO: Health Maintenance Organization; ICS: Inhaled corticosteroids; LABA: Long-acting b2-
agonists.
Y.M. Gagnon et al.1542which are specific to observational cohort studies,
will become clearer with the publication in 2006 of
a randomized controlled trial of these treatments
in COPD.56
Using a third party payer perspective meant that
indirect costs were not included in our study. Our
analysis was limited to health care charge data
contained in the medical claims of an HMO. Future
economic evaluations would benefit from adopting
a societal perspective that includes these indirect
costs, since COPD is a disease that has an important
impact on work absenteeism and lost productivity.
Another avenue of investigation is to develop a cost
utility model by incorporating information on
quality of life in the form of utilities among persons
with various degrees of COPD. This type of
information on the health status burden of COPD
exacerbations has been presented elsewhere.57
The lifetime analysis was based on the assumption
that the survival patterns over the remaining
lifetime of subjects follows similar trends to those
observed over the 36 months of data. This would
need to be further validated in the context of along-term follow-up study of survival in subjects
with COPD.
Because of these limitations, the results from our
analysis must be considered hypothesis-generating
and should be confirmed in prospective clinical
trials. However, our findings provide a useful point
of reference for further discussions on potential
treatments for this highly prevalent disease that
result in substantial economic burden worldwide.
Our results are similar to a recent Canadian
economic evaluation that compared persons with
different stages of receiving ICS. Those investiga-
tors conducted parallel sets of analyses assuming
that ICS improved quality of life only, and that
there was also a mortality benefit. Over the
lifetime of patients, ICS was cost-effective at
conventional levels for stages 2 and 3 COPD: CDN
$ 21,200 per quality adjusted life year without an
assumed mortality gain and CDN $2,900 per quality
adjusted life year when a mortality benefit was
included.58
There is an acute need to find effective, life-
extending treatments for persons with COPD. ICS,
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Figure 5 Cost effectiveness acceptability curves showing strategies most likely to be cost-effective for 1154 subjects
enrolled in the Lovelace HMO and diagnosed with COPD between 1995 and 2000—lifetime analysis. Note: The
willingness-to-pay is the maximum amount that a decision-maker would pay for a gain of one year in life expectancy. No
ICS or LABA is the most cost-effective option until willingness-to-pay reaches $6,107 per year of life gained. For a
willingness-to-pay between $6,107 and $27,575 per year of life gained, LABA is the most cost-effective treatment,
while the combination ICS+LABA would be the treatment of choice for a willingness-to-pay higher than $27,575 per year
of life gained. Abbreviations: HMO: Health Maintenance Organization; ICS: Inhaled corticosteroids; LABA: Long-acting
b2-agonists.
Economic evaluation of treatments for COPD 1543LABA or their combination represent promising
treatment options and are currently being tested
in randomized trials. If the impact on survival seen
in these trials compares to that seen in observa-
tional studies, LABA and the combination treat-
ment are likely to be cost-effective in the United
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